Real-World Prevalence and Outcomes of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors in the US: A Retrospective Claims Database Analysis

Real-World Prevalence and Outcomes of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors in the US: A Retrospective Claims Database Analysis

# Background Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder with C5 inhibitors (C5i), eculizumab and ravulizumab, being part of current treatment options. # Objectives To estimate the 5-year prevalence of PNH and describe the healthcare resource utilization and direct healthcare...

Full description

Saved in:
Bibliographic Details
Main Authors: Srinivas K Tantravahi, Dominick Latremouille-Viau, Raj Desai, Soyon Lee, Jincy Paulose, Anumaxine Geevarghese, Annie Guérin, Shravanthi Seshasayee, Mohin Chanpura, Glorian Yen
Format: Article
Language:English
Published: Columbia Data Analytics, LLC 2025-08-01
Series:Journal of Health Economics and Outcomes Research
Online Access:https://doi.org/10.36469/001c.142049
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.36469/001c.142049

Similar Items